Biohaven Pharmaceutical

+$0.25 (+0.24%) As of 3:35 PM UTC today

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BHVN and other ETFs, options, and stocks.

About BHVN

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders.

CEO

Vladimir Coric

Employees

825

Headquarters

New Haven, Connecticut

Founded

2013

BHVN Key Statistics

Market cap

Price-Earnings ratio

—

Dividend yield

—

Average volume

598.06K

High today

$105.86

Low today

$103.54

Open price

$103.85

Volume

32.05K

52 Week high

$151.51

52 Week low

$62.57

BHVN News

MarketWatchDec 6

Biohaven Pharma Names CEO Vlad Coric as Chairman, Names Matthew Buten CFO

By Michael Dabaie Biohaven Pharmaceutical Holding Co. Ltd. named its chief executive to the role of chairman and appointed a new chief financial officer. The

Analyst ratings

Buy

83.3%

Hold

16.7%

Sell

BHVN Earnings

-$2.97

-$1.98

-$0.99

$0.00

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Estimated

— per share

Actual

Expected Feb 28, Pre-Market

Why Robinhood?

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. View more

Biohaven Pharma Names CEO Vlad Coric as Chairman, Names Matthew Buten CFO

83%

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders.